Stability of glucagon-like peptide 1 and glucagon in human plasma
Nicolai J Wewer Albrechtsen, Monika J Bak, Bolette Hartmann, Louise Wulff Christensen, Rune E Kuhre, Carolyn F Deacon, Jens J Holst, Nicolai J Wewer Albrechtsen, Monika J Bak, Bolette Hartmann, Louise Wulff Christensen, Rune E Kuhre, Carolyn F Deacon, Jens J Holst
Abstract
To investigate the stability of glucagon-like peptide 1 (GLP-1) and glucagon in plasma under short- and long-term storage conditions. Pooled human plasma (n=20), to which a dipeptidyl peptidase 4 (DPP4) inhibitor and aprotinin were added, was spiked with synthetic GLP-1 (intact, 7-36NH2 as well as the primary metabolite, GLP-1 9-36NH2) or glucagon. Peptide recoveries were measured in samples kept for 1 and 3 h at room temperature or on ice, treated with various enzyme inhibitors, after up to three thawing-refreezing cycles, and after storage at -20 and -80 °C for up to 1 year. Recoveries were unaffected by freezing cycles or if plasma was stored on ice for up to 3 h, but were impaired when samples stood at RT for more than 1 h. Recovery of intact GLP-1 increased by addition of a DPP4 inhibitor (no ice), but was not further improved by neutral endopeptidase 24.11 inhibitor or an inhibitor cocktail. GLP-1, but not glucagon, was stable for at least 1 year. Surprisingly, the recovery of glucagon was reduced by almost 50% by freezing compared with immediate analysis, regardless of storage time. Plasma handling procedures can significantly influence results of subsequent hormone analysis. Our data support addition of DPP4 inhibitor for GLP-1 measurement as well as cooling on ice of both GLP-1 and glucagon. Freeze-thaw cycles did not significantly affect stability of GLP-1 or glucagon. Long-term storage may affect glucagon levels regardless of storage temperature and results should be interpreted with caution.
Keywords: degradation; glucagon; glucagon-like peptide-1; samples handling; storage.
© 2015 The authors.
Figures
References
- Holst JJ. The physiology of glucagon-like peptide 1. Physiological Reviews. 2007;87:1409–1439. doi: 10.1152/physrev.00034.2006.
- Wewer Albrechtsen NJ, Kuhre RE, Deacon CF, Holst JJ. Targeting the intestinal L-cell for obesity and type 2 diabetes treatment. Expert Review of Endocrinology & Metabolism. 2014;9:61–72. doi: 10.1586/17446651.2014.862152.
- Holst JJ. Incretin hormones and the satiation signal. International Journal of Obesity. 2013;37:1161–1168. doi: 10.1038/ijo.2012.208.
- Deacon CF, Kelstrup M, Trebbien R, Klarskov L, Olesen M, Holst JJ. Differential regional metabolism of glucagon in anesthetized pigs. American Journal of Physiology. Endocrinology and Metabolism. 2003;285:E552–E560. doi: 10.1152/ajpendo.00125.2003.
- Deacon CF, Holst JJ. Immunoassays for the incretin hormones GIP and GLP-1. Best Practice & Research. Clinical Endocrinology & Metabolism. 2009;23:425–432. doi: 10.1016/j.beem.2009.03.006.
- Kuhre RE, Albrechtsen NJW, Hartmann B, Deacon CF, Holst JJ. Measurement of the incretin hormones: glucagon-like peptide-1 and glucose-dependent insulinotropic peptide. Journal of Diabetes and its Complications. 2014 [in press] doi: 10.1016/j.jdiacomp.2014.12.006.
- Bak MJ, Albrechtsen NW, Pedersen J, Hartmann B, Christensen M, Vilsbøll T, Knop FK, Deacon CF, Dragsted LO, Holst JJ. Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans. European Journal of Endocrinology. 2014;170:529–538. doi: 10.1530/EJE-13-0941.
- Bak MJ, Wewer Albrechtsen NJ, Pedersen J, Knop FK, Vilsboll T, Jorgensen NB, Hartmann B, Deacon CF, Dragsted LO, Holst JJ. Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies. Diabetes, Obesity & Metabolism. 2014;16:1155–1164. doi: 10.1111/dom.12352.
- Nagakura T, Yasuda N, Yamazaki K, Ikuta H, Tanaka I. Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition. Metabolism: Clinical and Experimental. 2003;52:81–86. doi: 10.1053/meta.2003.50014.
- Orskov C, Jeppesen J, Madsbad S, Holst JJ. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. Journal of Clinical Investigation. 1991;87:415–423. doi: 10.1172/JCI115012.
- Wewer Albrechtsen N, Hartmann B, Veedfald S, Windeløv J, Plamboeck A, Bojsen-Møller K, Idorn T, Feldt-Rasmussen B, Knop F, Vilsbøll T, et al. Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels? Diabetologia. 2014;57:1919–1926. doi: 10.1007/s00125-014-3283-z.
- Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes. 1994;43:535–539. doi: 10.2337/diab.43.4.535.
- Wilken M, Larsen F, Buckley D, Holst J. New highly specific immunoassays for glucagon-like peptide-1 (GLP-1) Diabetologia. 1999;42(Supplement 1):A196.
- Holst JJ, Knop FK, Vilsbøll T, Krarup T, Madsbad S. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care. 2011;34:S251–S257. doi: 10.2337/dc11-s227.
- Dirksen C, Jorgensen NB, Bojsen-Moller KN, Kielgast U, Jacobsen SH, Clausen TR, Worm D, Hartmann B, Rehfeld JF, Damgaard M, et al. Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass. International Journal of Obesity. 2013;37:1452–1459. doi: 10.1038/ijo.2013.15.
- Idorn T, Knop FK, Jorgensen M, Holst JJ, Hornum M, Feldt-Rasmussen B. Gastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal disease. Kidney International. 2013;83:915–923. doi: 10.1038/ki.2012.460.
- Plamboeck A, Holst JJ, Carr RD, Deacon CF. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia. 2005;48:1882–1890. doi: 10.1007/s00125-005-1847-7.
- Huml M, Kobr J, Siala K, Varvarovska J, Pomahacova R, Karlikova M, Sykora J. Gut peptide hormones and pediatric type 1 diabetes mellitus. Physiological Research. 2011;60:647–658.
- Chambers AP, Kirchner H, Wilson–Perez HE, Willency JA, Hale JE, Gaylinn BD, Thorner MO, Pfluger PT, Gutierrez JA, Tschöp MH, et al. The effects of vertical sleeve gastrectomy in rodents are ghrelin independent. Gastroenterology. 2012;144:50–52e55. doi: 10.1053/j.gastro.2012.09.009.
Source: PubMed